Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

NCT00821977 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Vildagliptin
DRUG: Vildagliptin
DRUG: Placebo

Sponsor

Novartis